NCT00794131View on ClinicalTrials.gov

Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions

Advanced Cancers (Solid Tumors)

Interventions

BIOLOGICAL

GL-ONC1

a genetically-engineered vaccinia virus (encoding Renilla luciferase-Aequorea green fluorescent protein fusion, β-galactosidase, and β-glucuronidase )

Trial Locations (1)

Unknown

Royal Marsden Hospital, Surrey